Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction

Many studies have shown alterations of the hemostatic and fibrinolytic systems in patients with atherosclerotic disease, principally in levels of plasminogen activator inhibitor-1. However, in a large prospective study only fibrinogen, von Willebrand factor antigen, and tissue plasminogen activator...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arteriosclerosis, thrombosis, and vascular biology thrombosis, and vascular biology, 1997-01, Vol.17 (1), p.114-118
Hauptverfasser: Carroll, Veronica A, Griffiths, Margaret R, Geiger, Margarete, Merlo, Christoph, Furlan, Miha, Lammle, Bernhard, Binder, Bernd R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 118
container_issue 1
container_start_page 114
container_title Arteriosclerosis, thrombosis, and vascular biology
container_volume 17
creator Carroll, Veronica A
Griffiths, Margaret R
Geiger, Margarete
Merlo, Christoph
Furlan, Miha
Lammle, Bernhard
Binder, Bernd R
description Many studies have shown alterations of the hemostatic and fibrinolytic systems in patients with atherosclerotic disease, principally in levels of plasminogen activator inhibitor-1. However, in a large prospective study only fibrinogen, von Willebrand factor antigen, and tissue plasminogen activator antigen were found to be independent risk markers for acute coronary events. The present study evaluated the fibrinolytic system in coronary artery disease, paying particular attention to another inhibitor of fibrinolysis, plasminogen activator inhibitor-3, also called protein C inhibitor (PCI). One hundred fifteen nonanticoagulated male survivors of myocardial infarction were investigated for a range of hemostatic and fibrinolytic parameters that were compared with values in 87 age-matched healthy control male subjects. PCI active antigen was significantly (P < .03) elevated in the myocardial infarction group compared with the control group and was associated with the number of acute coronary events suffered (P = .005) but not with the severity of disease as determined by coronary angiography. Elevated PCI plasma levels can be considered as a risk marker for acute coronary events and might be of particular importance in the pathogenesis of this disease due to the interference of PCI in both the anticoagulant and fibrinolytic systems. (Arterioscler Thromb Vasc Biol. 1997;17:114-118.)
doi_str_mv 10.1161/01.ATV.17.1.114
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78803567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78803567</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4726-bf5dc3b9fd09bf1909ac877b466b7dec6c5b30151343595227082f61459457a43</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhk1pSJO0554KppTevJmR9WEdw5I2C1sSSNqrkGWJVaq1UsnekH8fLbvk0IMYad5nRsM7VfUZYYHI8RJwcfXwZ4FigSVB31VnyAhtKG_5-3IHIRvGKflQnef8CACUEDitTiUg4ZSdVeu7oPNW13cpTtaP9bJejRvf-ymmepXr62B3erJDXaT7Oe38LqZcR1f_eolGp8HrUAqcTmbycfxYnTgdsv10jBfV7x_XD8ubZn37c7W8WjeGCsKb3rHBtL10A8jeoQSpTSdETznvxWANN6xvARm2tGWSESKgI44jZZIyoWl7UX0_9H1K8d9s86S2Phsbgh5tnLMSXQct46KAX_8DH-OcxjKbIsWKTnJOCnR5gEyKOSfr1FPyW51eFILam6wAVTFZoVBYEvv_vxzbzv3WDm_80dWifzvqOhsdXNKj8fkNI2U0BlAwesCeY5hsyn_D_GyT2lgdpo3aL6vlwBqUUgCWZ1MO8vYV9nyRUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204289662</pqid></control><display><type>article</type><title>Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Carroll, Veronica A ; Griffiths, Margaret R ; Geiger, Margarete ; Merlo, Christoph ; Furlan, Miha ; Lammle, Bernhard ; Binder, Bernd R</creator><creatorcontrib>Carroll, Veronica A ; Griffiths, Margaret R ; Geiger, Margarete ; Merlo, Christoph ; Furlan, Miha ; Lammle, Bernhard ; Binder, Bernd R</creatorcontrib><description>Many studies have shown alterations of the hemostatic and fibrinolytic systems in patients with atherosclerotic disease, principally in levels of plasminogen activator inhibitor-1. However, in a large prospective study only fibrinogen, von Willebrand factor antigen, and tissue plasminogen activator antigen were found to be independent risk markers for acute coronary events. The present study evaluated the fibrinolytic system in coronary artery disease, paying particular attention to another inhibitor of fibrinolysis, plasminogen activator inhibitor-3, also called protein C inhibitor (PCI). One hundred fifteen nonanticoagulated male survivors of myocardial infarction were investigated for a range of hemostatic and fibrinolytic parameters that were compared with values in 87 age-matched healthy control male subjects. PCI active antigen was significantly (P &lt; .03) elevated in the myocardial infarction group compared with the control group and was associated with the number of acute coronary events suffered (P = .005) but not with the severity of disease as determined by coronary angiography. Elevated PCI plasma levels can be considered as a risk marker for acute coronary events and might be of particular importance in the pathogenesis of this disease due to the interference of PCI in both the anticoagulant and fibrinolytic systems. (Arterioscler Thromb Vasc Biol. 1997;17:114-118.)</description><identifier>ISSN: 1079-5642</identifier><identifier>EISSN: 1524-4636</identifier><identifier>DOI: 10.1161/01.ATV.17.1.114</identifier><identifier>PMID: 9012645</identifier><identifier>CODEN: ATVBFA</identifier><language>eng</language><publisher>Philadelphia, PA: American Heart Association, Inc</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Cardiology. Vascular system ; Coronary heart disease ; Fibrinolysis ; Heart ; Humans ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - blood ; Protein C Inhibitor - blood ; Risk Factors</subject><ispartof>Arteriosclerosis, thrombosis, and vascular biology, 1997-01, Vol.17 (1), p.114-118</ispartof><rights>1997 American Heart Association, Inc.</rights><rights>1997 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Jan 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4726-bf5dc3b9fd09bf1909ac877b466b7dec6c5b30151343595227082f61459457a43</citedby><cites>FETCH-LOGICAL-c4726-bf5dc3b9fd09bf1909ac877b466b7dec6c5b30151343595227082f61459457a43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,4050,4051,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2567500$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9012645$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carroll, Veronica A</creatorcontrib><creatorcontrib>Griffiths, Margaret R</creatorcontrib><creatorcontrib>Geiger, Margarete</creatorcontrib><creatorcontrib>Merlo, Christoph</creatorcontrib><creatorcontrib>Furlan, Miha</creatorcontrib><creatorcontrib>Lammle, Bernhard</creatorcontrib><creatorcontrib>Binder, Bernd R</creatorcontrib><title>Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction</title><title>Arteriosclerosis, thrombosis, and vascular biology</title><addtitle>Arterioscler Thromb Vasc Biol</addtitle><description>Many studies have shown alterations of the hemostatic and fibrinolytic systems in patients with atherosclerotic disease, principally in levels of plasminogen activator inhibitor-1. However, in a large prospective study only fibrinogen, von Willebrand factor antigen, and tissue plasminogen activator antigen were found to be independent risk markers for acute coronary events. The present study evaluated the fibrinolytic system in coronary artery disease, paying particular attention to another inhibitor of fibrinolysis, plasminogen activator inhibitor-3, also called protein C inhibitor (PCI). One hundred fifteen nonanticoagulated male survivors of myocardial infarction were investigated for a range of hemostatic and fibrinolytic parameters that were compared with values in 87 age-matched healthy control male subjects. PCI active antigen was significantly (P &lt; .03) elevated in the myocardial infarction group compared with the control group and was associated with the number of acute coronary events suffered (P = .005) but not with the severity of disease as determined by coronary angiography. Elevated PCI plasma levels can be considered as a risk marker for acute coronary events and might be of particular importance in the pathogenesis of this disease due to the interference of PCI in both the anticoagulant and fibrinolytic systems. (Arterioscler Thromb Vasc Biol. 1997;17:114-118.)</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Coronary heart disease</subject><subject>Fibrinolysis</subject><subject>Heart</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - blood</subject><subject>Protein C Inhibitor - blood</subject><subject>Risk Factors</subject><issn>1079-5642</issn><issn>1524-4636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1r3DAQhk1pSJO0554KppTevJmR9WEdw5I2C1sSSNqrkGWJVaq1UsnekH8fLbvk0IMYad5nRsM7VfUZYYHI8RJwcfXwZ4FigSVB31VnyAhtKG_5-3IHIRvGKflQnef8CACUEDitTiUg4ZSdVeu7oPNW13cpTtaP9bJejRvf-ymmepXr62B3erJDXaT7Oe38LqZcR1f_eolGp8HrUAqcTmbycfxYnTgdsv10jBfV7x_XD8ubZn37c7W8WjeGCsKb3rHBtL10A8jeoQSpTSdETznvxWANN6xvARm2tGWSESKgI44jZZIyoWl7UX0_9H1K8d9s86S2Phsbgh5tnLMSXQct46KAX_8DH-OcxjKbIsWKTnJOCnR5gEyKOSfr1FPyW51eFILam6wAVTFZoVBYEvv_vxzbzv3WDm_80dWifzvqOhsdXNKj8fkNI2U0BlAwesCeY5hsyn_D_GyT2lgdpo3aL6vlwBqUUgCWZ1MO8vYV9nyRUQ</recordid><startdate>199701</startdate><enddate>199701</enddate><creator>Carroll, Veronica A</creator><creator>Griffiths, Margaret R</creator><creator>Geiger, Margarete</creator><creator>Merlo, Christoph</creator><creator>Furlan, Miha</creator><creator>Lammle, Bernhard</creator><creator>Binder, Bernd R</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>199701</creationdate><title>Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction</title><author>Carroll, Veronica A ; Griffiths, Margaret R ; Geiger, Margarete ; Merlo, Christoph ; Furlan, Miha ; Lammle, Bernhard ; Binder, Bernd R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4726-bf5dc3b9fd09bf1909ac877b466b7dec6c5b30151343595227082f61459457a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Coronary heart disease</topic><topic>Fibrinolysis</topic><topic>Heart</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - blood</topic><topic>Protein C Inhibitor - blood</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carroll, Veronica A</creatorcontrib><creatorcontrib>Griffiths, Margaret R</creatorcontrib><creatorcontrib>Geiger, Margarete</creatorcontrib><creatorcontrib>Merlo, Christoph</creatorcontrib><creatorcontrib>Furlan, Miha</creatorcontrib><creatorcontrib>Lammle, Bernhard</creatorcontrib><creatorcontrib>Binder, Bernd R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Arteriosclerosis, thrombosis, and vascular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carroll, Veronica A</au><au>Griffiths, Margaret R</au><au>Geiger, Margarete</au><au>Merlo, Christoph</au><au>Furlan, Miha</au><au>Lammle, Bernhard</au><au>Binder, Bernd R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction</atitle><jtitle>Arteriosclerosis, thrombosis, and vascular biology</jtitle><addtitle>Arterioscler Thromb Vasc Biol</addtitle><date>1997-01</date><risdate>1997</risdate><volume>17</volume><issue>1</issue><spage>114</spage><epage>118</epage><pages>114-118</pages><issn>1079-5642</issn><eissn>1524-4636</eissn><coden>ATVBFA</coden><abstract>Many studies have shown alterations of the hemostatic and fibrinolytic systems in patients with atherosclerotic disease, principally in levels of plasminogen activator inhibitor-1. However, in a large prospective study only fibrinogen, von Willebrand factor antigen, and tissue plasminogen activator antigen were found to be independent risk markers for acute coronary events. The present study evaluated the fibrinolytic system in coronary artery disease, paying particular attention to another inhibitor of fibrinolysis, plasminogen activator inhibitor-3, also called protein C inhibitor (PCI). One hundred fifteen nonanticoagulated male survivors of myocardial infarction were investigated for a range of hemostatic and fibrinolytic parameters that were compared with values in 87 age-matched healthy control male subjects. PCI active antigen was significantly (P &lt; .03) elevated in the myocardial infarction group compared with the control group and was associated with the number of acute coronary events suffered (P = .005) but not with the severity of disease as determined by coronary angiography. Elevated PCI plasma levels can be considered as a risk marker for acute coronary events and might be of particular importance in the pathogenesis of this disease due to the interference of PCI in both the anticoagulant and fibrinolytic systems. (Arterioscler Thromb Vasc Biol. 1997;17:114-118.)</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>9012645</pmid><doi>10.1161/01.ATV.17.1.114</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1079-5642
ispartof Arteriosclerosis, thrombosis, and vascular biology, 1997-01, Vol.17 (1), p.114-118
issn 1079-5642
1524-4636
language eng
recordid cdi_proquest_miscellaneous_78803567
source MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection
subjects Adult
Aged
Biological and medical sciences
Cardiology. Vascular system
Coronary heart disease
Fibrinolysis
Heart
Humans
Male
Medical sciences
Middle Aged
Myocardial Infarction - blood
Protein C Inhibitor - blood
Risk Factors
title Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A36%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20Protein%20C%20Inhibitor%20Is%20Elevated%20in%20Survivors%20of%20Myocardial%20Infarction&rft.jtitle=Arteriosclerosis,%20thrombosis,%20and%20vascular%20biology&rft.au=Carroll,%20Veronica%20A&rft.date=1997-01&rft.volume=17&rft.issue=1&rft.spage=114&rft.epage=118&rft.pages=114-118&rft.issn=1079-5642&rft.eissn=1524-4636&rft.coden=ATVBFA&rft_id=info:doi/10.1161/01.ATV.17.1.114&rft_dat=%3Cproquest_cross%3E78803567%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=204289662&rft_id=info:pmid/9012645&rfr_iscdi=true